Coherus Biosciences | CHRS - Current Assets


Coherus Biosciences reported $206.71M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
AbbVie USD 33.53B 4.47B Mar/2026
Acadia Pharmaceuticals USD 1.1B 33.9M Mar/2026
Akebia Therapeutics USD 243.48M 9.47M Mar/2026
ALKERMES USD 1.52B 164.26M Jun/2026
Alnylam Pharmaceuticals USD 4.62B 400.86M Jun/2026
Amarin USD 602.76M 23.26M Jun/2026
Amgen USD 31.48B 2.42B Mar/2026
Baxter International USD 6.99B 142M Jun/2026
Biogen USD 7.31B 1.88B Jun/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Bristol-Myers Squibb USD 28.58B 1.37B Jun/2026
Coherus Biosciences USD 206.71M 254.25M Dec/2025
Eli Lilly USD 54.84B 794M Mar/2026
Fujifilm JPY 1.72T 2.2B Mar/2026
Gilead Sciences USD 18.64B 1.25B Mar/2026
Ironwood Pharmaceuticals USD 332.29M 58.11M Mar/2026
Merck USD 35.02B 8.5B Mar/2026
Myriad Genetics USD 289M 23.8M Jun/2026
Pacira USD 514.96M 33.01M Mar/2026
Perrigo USD 2.71B 85M Mar/2026
Pfizer USD 42.82B 76M Mar/2026
PTC Therapeutics USD 2.62B 363.36M Jun/2026
Regeneron Pharmaceuticals USD 18.45B 236.8M Jun/2026
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
Teva Pharmaceutical Industries USD 13.76B 50M Jun/2026
Vertex Pharmaceuticals USD 11.73B 529.3M Mar/2026
Xencor USD 482.85M 116.97M Mar/2026
Zoetis USD 6.47B 294M Mar/2026